New pill targets Hard-to-Treat cancers in early trial

NCT ID NCT06898450

Recruiting now Disease control Sponsor: Nimbus Wadjet, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new daily pill called NDI-219216 for people with advanced solid tumors that have not responded to standard treatments. The study will first check safety and side effects, then look at whether the drug can shrink tumors. About 134 participants will take the pill daily and have regular clinic visits for monitoring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NDI-219216 (a WRN inhibitor taken as a daily pill)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors, especially those with specific genetic features (MSI-H/dMMR).
What could go wrong: This is an early phase 1/2 trial with a small number of participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Microsatellite Instability neoplasm Werner syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CANCER MSI-H CANCER

Contacts and locations

Locations

Atrium Health Wake Forest Baptist Center
RECRUITING

Winston-Salem, North Carolina, 27157, United States
Brown University Health
RECRUITING

Providence, Rhode Island, 02901, United States
Cayuga Cancer Center
TERMINATED

Ithaca, New York, 14850, United States
Centre Hospitalier Universitaire (CHU) de Poitiers
RECRUITING

Poitiers, 86021, France
Hospital Clinico San Carlos
RECRUITING

Madrid, 28040, Spain
Hôpital Saint-Antoine - Assistance Publique-Hopitaux de Paris (AP-HP)
RECRUITING

Paris, 75012, France
Levine Cancer Center
RECRUITING

Charlotte, North Carolina, 28204, United States
Liverpool Hospital
RECRUITING

Liverpool, New South Wales, 2170, Australia
Princess Margaret Cancer Center
RECRUITING

Toronto, Ontario, M5G2C4, Canada
Prisma Health Cancer Institute - Multidisciplinary Center
RECRUITING

Greenville, South Carolina, 29605, United States
START Barcelona
RECRUITING

Barcelona, 08023, Spain
START Dublin
RECRUITING

Dublin, D07 R2WY, Ireland
START Lisbon
RECRUITING

Lisbon, 1649-028, Portugal
Sarah Cannon Research Institute UK
RECRUITING

London, W1G 6AD, United Kingdom
Southern Oncology Clinical Research Unit
RECRUITING

Bedford Park, South Australia, 5042, Australia
Taylor Cancer Research Center
RECRUITING

Maumee, Ohio, 43537, United States
The Christie NHS Foundation Trust UK
RECRUITING

Manchester, M20 4BX, United Kingdom
USC Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90089, United States
University of Chicago Medicine
RECRUITING

Chicago, Illinois, 60637, United States
University of Louisville James Graham Brown Cancer Center
RECRUITING

Louisville, Kentucky, 40202, United States
University of Virginia Emily Couric Clinical Cancer Center
RECRUITING

Charlottesville, Virginia, 22908, United States
Virginia Cancer Specialists, P.C. - Fairfax
RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.